Inserm
French National Institute of Health
and
Medical Research
• Created in 1964 from the
National Institute of Hygiene and
Hospital Research
• Working through the
Ministries for Research and Health
Szeged, Sept. 28th 2007
1
Inserm : key figures
335 Inserm laboratories
25 research centers
41 Clinical Investigation
Centers (CIC)
Budget 2007 : 700 M€
Total staff: 13 000
(2 500 physicians) of which
4900 Inserm employees: 2100 scientists and 2800
technical staff
(62% of total budget dedicated to salaries)
An active patent
portfolio of 572 families
374 French and foreign firms
are partners of Inserm
56 start-up companies based on Inserm technology
Szeged, Sept. 28th 2007
2
What is Inserm ?

The French performing research organisation entirely dedicated
to Biomedical & Clinical research and Public Health

All fields of research are covered in these domains


90% of the 335 research units are located in University hospitals
Research units with 8 years mandate with mid-term (4 year)
evaluation. Stringent evaluation

Investigator- driven projects - AVENIR programme

Close collaboration with French Funding agencies (ANR, INCa
ANRS), Sanitary agencies (InVS, AFSSAPS), Charities (AFM, …)
and industrial partners.
Szeged, Sept. 28th 2007
3
The Inserm performance
about:blank
Szeged, Sept. 28th 2007
4
Organization
 Bottom-up initiatives: selection based on
quality and innovation
 Networks focused on major public health
issues: “National Research Programs”:
- Diabetes, Cardiovascular, Hepato-GastroEnterology
- Bone and joint diseases, endocrinology and
reproduction etc….
Szeged, Sept. 28th 2007
5
Infectious diseases
and microbiology
(without Aids and Hepatitis)
Public health
7.5%
Handicap
5.1%
Nutrition
4.8%
8.3%
AIDS
3.7% Hepatitis
3.1% Diabetes
2.6%
Cardiovascular
diseases
Bone and Joint
Diseases
2.2%
9.1%
Genetic
diseases
10.5%
Neurosciences
20.6%
of which 9.3%
for neurologic
disorders
16.8%
Cancer
17.1%
Immunology
Research laboratories being often involved in more than one domain, the overall distribution is over 100 %
Szeged, Sept. 28th 2007
6
Hospitals
Universities
National research
& Public health
agencies
Research organizations
CNRS, CEA, Inra, Inria,
IRD, Pasteur Institute,
Curie Institute
Szeged, Sept. 28th 2007
Industry
International
scientific
community
Scientific & medical
societies, Patients
associations, Foundation,
Charities
7
Inserm : creation of research centers

Objectives and main characteristics:
• Critical mass (100 to 300 staffs),
• Mutualisation and Integration
• International visibility, Attractiveness

Assessment criteria:
• Scientific excellence
• Quality of the management :
Governing structure, mutualised administration & management
Technology transfert and research outcomes
Sharing of technical facitilies
Coordination of scientific events and programmes
Implementation of research training programmes
International scientific council for evaluation of scientific strategy (turnover of scientific teams : mobility, hosting new scientists or teams,…)
Szeged, Sept. 28th 2007
8
25 Research Centers in 2007
Some exemples:
1- Paris 6, Pluri-thematic
2- Paris 6, Neurophysiology
4- Paris 5, Pluri-thematic
5- Créteil, Pluri-thematic
6- Lilles, Pluri-thematic
7- Dijon, Cancer/Nutrition
8- Bordeaux, Neurophysiology
9- Grenoble, Neurophysiology
10- Grenoble, Cancer
11- Toulouse, Pluri-thematic
Szeged, Sept. 28th 2007
9
Director : D.Moras
Inserm Unit 596
7 departments
550 staffs
Strasbourg
3 Avenir programs
Facilities
Partners
Thematics
- Inserm
- Louis Pasteur University
- CNRS
- Molecular pathology
- Developmental and physiological gentics
- Fonctional genomics
- Cellular biologie and signal transduction
- Molecular neurobiology
- Cellular imaging
- DNA microarray platform
- Monoclonal Antibody
- Structural biology
- Bio-informatic
- Protéomics
Technology transfer
- > 20 contrats with industries
- Public-private Partnerships
www-igbmc.u-strasbg.fr
Szeged, Sept. 28th 2007
10
Centre de recherche Jean-Pierre Aubert
JPARC
Director : Pierre Formstecher
Inserm Unit 837
5 teams
150 staffs
Lille
Facilities
- Proteomics
- Biotherapy
- Cytometry
- Cellular imaging
- Animal imaging
Thematics
- Neurosciences
- Cellular différenciation and cancer
Partners
- Lille 2 University
- Lille University Hospital
- Inserm
Technology transfer
- Public-private Partnerships
www.crjpa.lille.inserm.fr
Szeged, Sept. 28th 2007
11
Institut du Fer à Moulin
IFM
Director : Jean-Antoine Girault
Partners
Inserm Unit 839
19 teams
99 staffs
Paris
1 Avenir program
- Université Paris 6
- Paris University hospital
- Inserm
Thematics
Signalling mechanisms involved in the
nervous system developpement
Facilities
- Animals
- Cellular imaging
- Quantitative PCR
- Cytometry
- Peptide synthesis
- Proteomics
Szeged, Sept. 28th 2007
Technology transfer
- Public-private Partnerships
12
Evolution of Research Units and Research
centers at Inserm (from 2001 to 2007)
Szeged, Sept. 28th 2007
13
Research infrastructures
• National Genomic Research Consortium: CNRG
National Sequencing Center
National Genotyping Center
Regional Genopoles Core Facilities
• Biosafety-level 4 laboratory
• Local and regional technological plateforms
• Clinical Research Infrastructures
Szeged, Sept. 28th 2007
14
Research platforms
1
Lille
1
1
1
2
Sequencing
9
Transcriptomics
6
11
13
Rouen
Caen
1
1
4
1
1
6
4
1
1
Paris 1
1
1
1
Proteomics
1
1
1
Rennes
Cellular imaging
4
Electronic microscopy
5
Functional exploratory platform/animals
1
1
in vivo imaging
Tours
1
Reims
Nancy
Strasbourg
Orléans
1
1
1
1
1
2
1
1
1
1
Dijon
Nantes
Poitiers
1
6
2
Animal experimentations
Vegetal experimentations
4
Structural biology
8
Bioinformatic
1
1
ClermontFerrand
1
Toulouse
1
Human biological resources
1
Bacterial
1
Chemistry
Szeged, Sept. 28th 2007
1
1
1
1
Lipidomics
National Biological resources :
1
Lyon
Grenoble
1
Bordeaux
1
1
1
1
1
1
1
1
1
1
Montpellier
1
1
1
Rousset
Marseille
1
1
1
1
2
1
Nice
15
Main Inserm’s priorities
1. « Researchers » : Careers, Training & Mobility
2. To focus Inserm on its main mission: support both
basic and clinical research; develop translational
research with a multidisciplinary approach
3. To establish Inserm in a European and International
context
4. To develop public/private partnerships
Szeged, Sept. 28th 2007
16
Researchers :
Career, Training and Mobility
Szeged, Sept. 28th 2007
17
Career tracks at Inserm
• Junior, temporary contract (5 years with a 3-year
intermediate evaluation), high level (research
director) contracts
Avenir program
European programs: EURYI, ERC
• Permanent positions for senior scientists
Szeged, Sept. 28th 2007
18
AVENIR Programme
• Eligibility: Young scientists with permanent or temporary
position, clinicians
• Aim: To strengthen the status of young scientists; to
recognize, evaluate and continuously promote scientific
qualities
• A yearly budget of 200K euros for 5 years
• Minimum lab space of 50 m2
• Running costs
• Salaries, human resources (Post-doc, engineers,
technicians)
Szeged, Sept. 28th 2007
19
Interface contracts : General principles
• Based on :
a permanent position + temporary, 3-5 year contracts
• To reinforce interactions with partners and mobility
- Hospitals: clinical research, medical issues
- Health agencies: health policy issues
- Universities: teaching, making scientific
information available to the society
• Industry: technological transfer and valorisation
• European partners / European mobility (a new scheme of
the Marie Curie actions - PEOPLE programme ?)
Szeged, Sept. 28th 2007
20
Interface contracts for Inserm scientists :
Tenure position + 3-5 year contracts: " 2/3 – 1/3 "
Hospital
Industry
International
institutions
University
Tenured
scientists
Sanitary Agencies
« Internal » Inserm
Szeged, Sept. 28th 2007
21
Interface Contract grants for MDs
• Reinforce research activities of clinicians and
university research assistants and professors
• 3-5 year contracts for clinicians : assistant professors and
professors, university employees
• Grant paid by Inserm to hospitals and universities to be
used for :
- clinical and teaching activities: temporary positions
- financing research activities
Szeged, Sept. 28th 2007
22
The School of Inserm
A 3-year Theoretical and Practical
Education which leads to a Master’s
• First year of Inserm School - Second year of Medical School :
 Special School Intensive Training Session in
February
 June: Competitive Exam
• Second year of Inserm School - Third year of Medical School
 6 month full time Research Clerkship in an
Inserm Research Laboratory
• Third year of Inserm School - Interruption of Medical School :
Clerkship in a Research Laboratory and educational program for
the Master Degree
Szeged, Sept. 28th 2007
23
Clinical research
and Translational research strategy
Szeged, Sept. 28th 2007
24
Clinical trials
Inserm
Basic
Research
Preclinical
studies :
Proof of concept
Szeged, Sept. 28th 2007
Inserm
Proof of
concept
Phases I-IIa
Biotherapy
[CRC]
Inserm
Phases
IIb-III
Phase IV
Cohorts
25
Inserm, as a major actor of the Clinical
Research in France and in Europe
• To set-up an efficient Translational research towards the
benefits of patients
• To develop dedicated performing Research
Infrastructures : ECRIN, GMP facilities platforms
(innovative biomedicines), BRCs, (Roadmap ESFRI)
• To sponsor clinical studies and innovative therapeutic
clinical trials
• To ensure appropriate training of Physicians to Research
skills and vice-versa : School of Inserm
• To built a continuum from Basic research to Clinical
Research
Szeged, Sept. 28th 2007
26
Clinical research infrastructures
2006
2001
2002
2003
2004
2005
Clinical research
centers
41
17
21
28
31
41
Tissues Banks
47
16
30
47
47
47
118
131
135
142
147
147
Registries
35
17
29
29
31
35
Networks
22
9
22
22
22
22
Cohorts
Szeged, Sept. 28th 2007
27
41 Clinical Investigation Centres
•
•
•
CIC
Epidemiology
studies
Biotherapy
Access to patients
Support to investigators
Szeged, Sept. 28th 2007
28
Finland
FinnCRIN
Sweden
SweCRIN
Ireland
ICRIN
UK
UKCRN
Denmark
DCRIN
EORTC
Germany
KKS
France
Inserm
Spain
SCReN
EFGCP
Austria
ATCRIN
Switzerland
SCRN
Hungary
HECRIN
Italy
IRFMN & CIRM
European
Clinical
Research
Infrastructures
Network, coordinated by
INSERM:
Pan-European
infrastructure
providing
services to the
preparation
and the
conduct of
multinational
clinical studies,
with GMP
facilities for
biotherapy
National
networks of Clinical Research Centres / Clinical Trial Units
Szeged, Sept. 28th 2007
29
Biological Resources Centres
a networking action at both
National and European Levels
Szeged, Sept. 28th 2007
30
Network of Biological Resources Facilities
Cohorts of Patients
• Science Case:




A European network to coordinate European Scientific programs
and policies
Clinical data and follow-up of patients and Healthy volunteers
Innovative targets, biomarkers, clinical studies
Technology transfer, dissemination of knowledge, valorisation
• Technical case:

Repositories for qualified biological samples (DNA, RNA,
proteins,…), coupled to clinical data.

Providers/distributors of samples within scientific project objectives

Development of QA standards for European BRCs

To store samples for the future (heritage)

Distributed facilities / centralised database
Szeged, Sept. 28th 2007
31
European Biological Resources network (BBMRI)
The necessity of a European network :
 To co-ordinate European scientific programs and
policies : 7th PCRD
 To develop and harmonize assurance-quality
standards for European BRCs : exchanges of
authenticated biological materials.
 Valorisation of knowledge
 Attractiveness of public research and development
of innovative SMEs.
Szeged, Sept. 28th 2007
32
Platforms for GMP production
State of the art :
 Platforms for production of therapeutic vectors : Nantes
(Atlantic biothérapies), Généthon, etc.
 Platforms for production of bio-medicines : LFB, Genopole
Ile-de-France, Vivalis, Lipidomix, etc.
 Platforms for production of therapeutic virus : Heidelberg
Perspectives : availability of GMP products
 Partnership with Inserm-Transfert
 Costs sharing
 European dimension : ESFRI / IMI
Szeged, Sept. 28th 2007
33
EU approach for of GMP Facilities
• Needs : to develop innovative “non-commercial” clinical trials - Lack
of specific financial support
• Science Case:


Reinforcing clinical research and translation of basic research to
therapy
Production and evaluation of innovative therapeutic and
diagnostic agents : biomarkers and biotherapy / regenerative
medicine : cell therapy, gene therapy, tissue engineering
• Technical case:

Production of new therapeutic/diagnostic agents from
biotechnologies

Products for Cell and Gene therapy

Good Manufacturing Practices (GMO dissemination regulation), in
line with national legislation, able to cooperate across the borders

Direct links with Clinical Research Centres (CRC - ECRIN)
Szeged, Sept. 28th 2007
34
IMI : Innovative Medicines for Europe
European Joint Technology Initiative (JTI) to develop new
therapeutic drugs in a faster and safer way.
Inserm is the French representative in the Member states
contact Group of IMI
Szeged, Sept. 28th 2007
35
Competitivity Clusters
Nutrition Santé Longévité
Innovations thérapeutiques
Medicen
Imaging, Cancer,
Biotehrapy, Neurosciences
Atlantic Biothérapies
Qualitropic
Lyonbiopôle
Virology
Prod’Innov
International
National
Emergent
Réunion
67 created clusters
7 involving Inserm units
Szeged, Sept. 28th 2007
Cancer Bio Santé
Orpheme
Nutrition
36
The European policy of Inserm
Szeged, Sept. 28th 2007
37
Inserm’s priorities in Europe
1. « Researchers » : attractive careers, training, mobility
2. “European” Research Laboratories:
European Associated Laboratories, Joint Unit abroad
3. Research Infrastructures for biomedical research
(ECRIN, Biobanks, EATRIS) and Translational research
based on Public-Private Partnership (IMI - European Joint
Technology Initiative)
4. FP7 and other European programmes of interest
5. EU Prospectives (ESF-EMRC, EUROHORCS,etc.)
=> Green paper on new perspectives of ERA
Szeged, Sept. 28th 2007
38
Multilateral cooperations’ actions
Inserm in FP6
• around 150 EU research projects
• 224 participating research teams
• 26 in coordination
Inserm in FP7
First call of the Health priority :
Total of 152 selected projects, out of which
7 coordinated by Inserm
(preliminary data)
Szeged, Sept. 28th 2007
39
Bilateral cooperations’ actions
 Researchers' mobility (short-medium term, Interface
Contract grants)
 European research networks at the bilateral level and
within the EU programmes
 European Associated laboratories
 Joint Research unit abroad
Szeged, Sept. 28th 2007
40
Bilateral cooperations’ tools:
Associated Laboratories and Inserm’s Units abroad

Scientifically driven

8 years mandate with mid-term evaluation

Synergies: competencies and facility access

Co-funded by Inserm and Associated partner

Temporary/permanent positions (Mobility of Post-Doc,
researchers - Interface contracts)

Institutional “label”

Leverage effect for additional funding
Szeged, Sept. 28th 2007
41
 European Associated Laboratories (LEA)
Toulouse : D. Langin U586 / Prague : V. Stich (Univ. Charles)
Lille : M. Capron U547 / Brussels : M. Goldman (IMI)
Toulouse : AC Prats U589 / Dundee : JC Bourdon (Univ. Dundee)
Bordeaux: A. Bikfalvi E 113 / Milan: L. Bello (Univ. Degli Stuli)
Nice: G. Meneguzzi U 634 / Rome: G. Zambruno (IDI-IRCCS)
Villejuif: D. Samuel U 785 / Rome: M. Levrero (Univ. La Sapienza)
Montpellier: K. Ritchie U 888 / London: G. Thornicroft (King’s College of London)
Strasbourg: T. Baumert U 748 / Freiburg: H. Blum (Univ. of Freiburg)
Villejuif: T. Moreau U 780/ Barcelona: J. Antό (PRBB, IMIM-CREAL)
Bordeaux: L. Bordenave U 577 / Porto: M. Barbosa (IBMC, INEB)
Glasgow
Dundee
Joint Research Unit in Europe:
London
Université de Glasgow / C. Doerig U609
Brussels
DKFZ / J. Rommelaere U701
Prague
Freiburg
Barcelona
Porto
Szeged, Sept. 28th 2007
Heidelberg
Milan
Rome
42
Laval
Montreal
Montreal
Los Angeles
Irvine
New York
Rabat
Pittsburgh
Beijing
Haïfa
Seoul
Wuhan
Nanjing
Dallas
Doha
Tokyo
Kyoto
Shanghai
Guangzhou
Singapour
Rio de
Janeiro
Buenos
Aires
Szeged, Sept. 28th 2007
INSERM Unit
Associated Laboratory
In preparation
43
European Mobility of Researchers
« Towards a European Career Track »

International Cooperation Contracts (up to 4 years)
Salary paid by “home” institution + additional salary
paid by “host” institution
 Reciprocal, bi-directional (Imperial College London,
CNR,…)

=> Marie Curie « Co-fund » Programme (FP7)

Joint Post-doctoral training contracts
2 phases, commitment for a contractual recruitment when they
return, bidirectional call for applications

Prospectives towards Internationalisation of School of
Inserm
Szeged, Sept. 28th 2007
44
Joint post-doctoral career track
• 3-year post-doctoral positions in host institutions:
Joint selection with Inserm
Joint calls under preparation with European
institutions (ICL, Univ. Dundee, Porto…)
• Evaluation at the end of post-doctoral fellowship
• Junior, 5-year Inserm contract
• Tenure: Inserm, CNRS, University, industry etc ..
Szeged, Sept. 28th 2007
45
Cooperations between Inserm and
Hungarian Partners
148 joint publications Inserm – Hungarian partners since 2000
Main Partner Institutions : Institutes of the Hungarian Academy
of Sciences (BRC Szeged), Semmelweis University Budapest,
University of Debrecen
Main thematic areas : Neurosciences, Cardiovascular
diseases, Molecular and Cell Biology, Biochemistry etc.
6 Hungarian Researchers and Fellows within Inserm's research
units in 2006
18 FP6 projects involving Inserm and Hungarian partners
(6 NoEs - 10 IPs - 2 STREP)
Further FP7 collaborations (IMI, ECRIN, BRCs…)
Szeged, Sept. 28th 2007
46
Transfert
• Inserm’s private subsidiary
• Created in 2001, funded up to € 4,5 million
• 60 people with scientific/industrial background
Missions:
• Drive value creation from Inserm research
• Allow an efficient partnering with the Industry
• Ensure a fair economic return towards Inserm
• Contribute to economic development
Szeged, Sept. 28th 2007
47
Transfert
Integrated Technology Transfer Skills
“From the bench to the partnering and the license”
Inserm
Research
Detectio
n of
Intellectual
Property
License
Biotec
h
Invention
s
Development of services
covering the whole technology transfer process :
start• Detection of inventions / “coaching”
up
•
•
•
•
•
•
•
•
Protection of inventions & follow up / intellectual property management
Pre-technology transfer / Applied and Translational Research
Technology Transfer, collaborative and R&D agreements
Preclinical Development / Proof of Concept development
Industrial Partnerships / Clinical trials development
International and European projects management
Biotech start up coaching and funding (pre seed fund Inserm Transfert Initiative)
Legal and financial expertise
Proximity between both scientific and industrial communities
for a best partnership development
Szeged, Sept. 28th 2007
48
Contacts :
Inserm’s web site : www.inserm.fr/en/inserm
Department of French Regional and European Strategic Policies
• Anne Bisagni, Director : anne.bisagni@tolbiac.inserm.fr
• Philippe Arhets, Deputy Director : philippe.arhets@tolbiac.inserm.fr
• Cécile Bergouignan, Bilateral cooperation :
cecile.bergouignan@tolbiac.inserm.fr
Human Resources : Researchers task force
• Anne-Marie Laffaye, School of Inserm, Avenir :
anne-marie.laffaye@tolbiac.inserm.fr
• Richard Salives, Marie Curie Programme :
richard.salives@tolbiac.inserm.fr
Szeged, Sept. 28th 2007
49